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Abstract
Background: Disordered bone mineral metabolism and low vitamin D concentrations are 
associated with cardiovascular abnormalities; few studies have evaluated this relationship in HIV-
infected youth.
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Setting: Adolescent Master Protocol (AMP) is a Pediatric HIV/AIDS Cohort Study (PHACS) 
network study conducted across 14 United States sites.
Methods: Among perinatally HIV-infected (PHIV) and HIV-exposed uninfected (PHEU) youth 
enrolled in AMP, we evaluated associations of vitamin D (measured as 25-hydroxyvitamin D 
[25OHD]), parathyroid hormone (PTH), calcium, phosphate, and fibroblast growth factor-23 
(FGF-23) concentrations with echocardiographic measures of left ventricular (LV) structure, 
function and concentrations of NT-proBNP, a biomarker of cardiac damage.
Results: Among 485 participants (305 PHIV, 180 PHEU) with echocardiograms and bone 
mineralization measures, low 25OHD (< 20 ng/mL) was common among all participants (48% 
PHIV and 44% PHEU), but elevated PTH (> 65 pg/mL) was identified more often among PHIV 
than PHEU participants (9% vs 3%, p=0.02). After adjusting for HIV status and demographic 
covariates, both low 25OHD and elevated PTH were associated with lower mean LV mass z-
scores, while elevated PTH was associated with higher mean fractional shortening z-scores. 
Participants with low 25OHD also had slightly higher mean LV end-systolic wall stress z-scores, 
but differences were more pronounced in PHEU than in PHIV participants. FGF-23 was inversely 
related to end-diastolic septal thickness both overall and among PHIV participants.
Conclusion: In this cohort of PHIV and PHEU youth, we observed associations of 25OHD, 
PTH, and FGF-23 with both structural and functional cardiac parameters, supporting links 
between bone mineral metabolism and cardiac status.
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Introduction
Disordered bone metabolism and low bone mineral density are common in both adults and 
children with HIV disease1–3. We have demonstrated lower total body and lumbar spine 
bone mineral density in children with perinatal HIV infection (PHIV) than in those who 
were perinatally HIV-exposed but uninfected (PHEU)3, along with a high prevalence (40%) 
of vitamin D insufficiency (VDI) in both PHIV and PHEU children4. Increasing evidence 
suggests that VDI is associated with several common cardiovascular abnormalities. An 
analysis of over 41,000 adults demonstrated highly significant inverse associations of 25-
hydroxyvitamin D (25OHD) levels and the prevalence of type 2 diabetes mellitus, systemic 
hypertension, dyslipidemias, and peripheral vascular disease5. In a group of HIV-infected 
youth, standard doses of 25OHD supplementation (18,000 IU/month vitamin D3) were 
shown to decrease carotid bulb intimal medial thickness, a marker for subclinical 
atherosclerosis6. Various mechanisms have been proposed to explain 25OHD contributions 
to the development of cardiovascular disorders, in both HIV and general populations, 
including inflammation, alterations in insulin sensitivity, and inhibition of the renin-
angiotensin-aldosterone axis.6,7
Derangements in other factors affecting bone mineralization, such as parathyroid hormone 
(PTH) and phosphate, have also been associated with subclinical myocellular damage. In 
pediatric patients with chronic renal failure, higher cardiac troponin T (cTnT), a marker of 
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myocardial injury, was associated with reduced PTH and elevated phosphate8. Low PTH 
concentrations have also been associated with left ventricular dilation in adults with chronic 
renal failure, although the mechanism underlying this relationship is not clear.
While disordered mineral metabolism is associated with cardiovascular disease, establishing 
a causal relationship is difficult because bone mineral metabolism markers are highly linked 
and involved in complex regulatory feedback loops. Recently, fibroblast growth factor-23 
(FGF-23) has been found to be a primary regulator of phosphate metabolism. FGF-23 is a 
peptide hormone secreted primarily by osteocytes. It reduces the reabsorption of phosphate 
in the proximal renal tubules, reducing systemic 1,25-dihydroxyvitamin D (1,25OHD) 
concentrations through diminished production and increased degradation of 1,25OHD and 
suppression of PTH transcription and secretion9. Elevated concentrations of FGF-23 directly 
correlate with increased left ventricular (LV) mass in patients with chronic kidney disease10. 
Given its importance in other clinical situations, evaluation of a potential role for FGF-23 in 
the cardiovascular status of children with HIV and those exposed prenatally to HIV is 
warranted.
Even though abnormal serum concentrations of bone mineral metabolism (BMM) markers 
(i.e., 25OHD, PTH, calcium, phosphate, and FGF-23) are common in HIV-infected 
populations, particularly among those receiving combination antiretroviral therapy4,11,12, 
and are associated with adverse cardiovascular conditions including congestive heart 
failure13,14, it is unknown whether these markers are associated with echocardiographic 
findings or with NT-proBNP, a biomarker of cardiac function. The objectives of this study 
were to evaluate associations of BMM marker concentrations with cardiac structure and 
function (as measured by echocardiography and NT-proBNP) in a population of PHIV and 
PHEU children, and to descriptively evaluate whether these associations vary by HIV 
infection status. Additionally, given the higher incidence of VDI in persons of black race, 
associations within this specific population were separately explored.
Methods
The National Institutes of Health-funded Adolescent Master Protocol (AMP) is a 
prospective cohort study conducted by the Pediatric HIV/AIDS Cohort Study (PHACS) 
network at 14 sites across the United States. Patients were enrolled between March 2007 and 
November 2009, with ongoing follow-up visits. The study was designed to define the impact 
of HIV infection and antiretroviral therapy on pre-adolescents and adolescents infected 
perinatally (PHIV). A group of perinatally HIV-exposed but uninfected children (PHEU) 
within the same age range and similar sociodemographic backgrounds was also enrolled. 
The study was approved by each site’s Institutional Review Board and by the Harvard T.H. 
Chan School of Public Health, Boston, MA. Written informed consent was provided by each 
parent or guardian, and assent was obtained as directed by the Institutional Review Board at 
each study site.
Measures of bone metabolism
BMM markers, including 25OHD, PTH, calcium, phosphate, and FGF-23, were measured in 
PHIV and PHEU children in AMP who had an adequate echocardiogram performed within 
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one year of the sample for BMM markers. Full details of the BMM marker assays used have 
been reported by Jacobson et al4. FGF-23 was measured by ELISA (Kainos Laboratories) 
and levels were log10-transformed to more closely approximate a normal distribution. In 
most cases, duplicate aliquots were assayed and the arithmetic mean reported. To enhance 
clinical interpretation, 25OHD and PTH concentrations were dichotomized: those with 
25OHD levels < 20 ng/mL were defined as having VDI and those with PTH values > 65 
pg/mL were considered to have an elevated PTH.
Echocardiographic variables and NT-proBNP concentrations
PHACS-trained site staff obtained a single echocardiogram from each patient, with all 
measurements performed centrally at the echocardiographic core laboratory at Children’s 
Hospital Boston to enhance reproducibility15. Z-scores were calculated based on a reference 
population of healthy children. Echocardiographic z-scores for the following LV function 
parameters were obtained: contractility, LV ejection fraction, and fractional shortening. 
Cardiac structure was assessed with echocardiographic z-scores for LV mass, LV end-
diastolic (ED) volume, LV end-systolic (ES) volume, LV ED wall thickness, LV ED 
dimension, M-mode thickness-to-dimension ratio, ES wall stress, and ED septal thickness. 
Concentrations of NT-proBNP were measured by standard techniques at the University of 
Miami (Dr. Armando Mendez). Values below the detection limit were reported as less than 5 
pg/mL. Concentrations of NT-proBNP were log10-transformed to achieve a more normal 
distribution. The cardiac measures of primary interest were fractional shortening, LV mass, 
contractility, LV ED wall and septal thicknesses, and NT-proBNP concentrations. Indicators 
of worse cardiac status included: lower z-scores for fractional shortening and contractility 
higher z-scores for LV mass, LV ED wall thickness, and septal thickness; and higher levels 
of NT-proBNP.
Potential confounders
The following variables were considered as potential confounders or independent predictors 
of the echocardiographic and NT-proBNP outcomes: age, race, ethnicity, sex, body mass 
index (BMI), region (Northeast, Midwest, South, West, or Puerto Rico), and physical 
activity (hours per day based on the BLOCK physical activity assessment). For analytic 
purposes, physical activity was categorized into four groups (< 30, 30–60, 60–120, and >120 
min/day), and was considered as an ordinal variable after confirming trends in outcomes. 
While seasonality is well known to affect vitamin D levels, it would not be expected to have 
an effect on the outcome measures (echocardiographic variables and NT-proBNP 
concentrations). Preliminary analysis confirmed that seasonality did not affect outcomes and 
also had little impact on estimated associations of bone metabolism markers with the 
outcomes, and therefore is not included here as a potential confounder.
Among PHIV youth, the distribution of HIV disease severity measures (i.e., CD4, HIV-1 
RNA viral load, and CDC class) and type and duration of antiretroviral treatment (ART) 
were considered. CD4 and HIV measures were included in the analysis if they were obtained 
between 6 months prior to or within 7 days after the date of the echocardiogram. Duration of 
ART regimens was calculated up to the date of the echocardiogram.
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Comparisons of mean echocardiographic measurements by HIV status, VDI, and elevated 
PTH status were conducted with two-sample T-tests and Wilcoxon rank sum tests for 
continuous variables and with Fisher’s exact test or Pearson Chi-Square test for categorical 
measures. A similar approach was used to compare median BMM marker concentrations by 
HIV status.
Univariable and multivariable linear regression models were fit to evaluate the association of 
BMM marker concentrations with cardiac outcomes of interest. 25OHD and PTH were 
analyzed as dichotomous predictors as previously noted, while all other BMM markers 
(calcium, phosphate, and log10 FGF23) were analyzed as continuous predictors. In addition 
to considering low 25OHD and elevated PTH concentrations separately, we also considered 
a combined measure of either low 25OHD and/or elevated PTH concentrations. However, 
the results of the combined measures were largely similar to those for low 25OHD and are 
not reported here. For the cardiac biomarker outcome, log10 NT-proBNP, sensitivity analyses 
were conducted using censored linear regression models to take into account values that 
were left-censored because they were below the detection limit.
Multivariable linear models for most cardiac outcomes of interest were adjusted by HIV 
status, age at echocardiogram, sex, race, BMI z-score, and physical activity. However, for 
fractional shortening, adjusted models included HIV status, region, and physical activity, 
while those evaluating the association of ES wall stress with BMM marker concentrations 
were adjusted by HIV status, age, region, and physical activity. These confounders were 
selected based on a priori decisions based on the literature, and by observing the change in 
effect estimates when adding each covariate separately to our regression models.
We evaluated whether the association of 25OHD status with echocardiographic variables and 
log10 NT-proBNP concentrations varied by HIV infection status both descriptively, by 
calculating adjusted least square means for echocardiographic z-scores by 25OHD status 
within each HIV infection group (calculated at mean levels of all other covariates in model), 
and with interaction terms between HIV status and VDI in adjusted linear regression 
models. Exploratory analyses were also conducted to assess the association of BMM marker 
concentrations with cardiac outcomes among the cohort of patients with self-reported black 
race, who are more likely to have VDI.
SAS version 9.4 was used for all statistical analyses. All statistical tests were two-sided with 
p-value < 0.05 indicating significance, although emphasis was placed on consistency of 
results across analyses.
Results
Of the 678 enrolled participants, 513 had evaluable echocardiograms and no history of 
congenital cardiac disorders. Among these 513 participants, 485 youth (95%; 305 PHIV and 
180 PHEU) had all or some BMM marker measurements obtained, with most on the same 
date as the echocardiogram. A smaller subgroup of 404 youth had NT-proBNP 
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measurements and, of these, 383 (95%; 231 PHIV and 152 PHEU) had at least one BMM 
marker measurement available (Supplemental Figure 1).
Table 1 presents the baseline sociodemographic characteristics by cohort of the 485 youth 
with evaluable echocardiograms and BMM markers. PHIV youth were older (mean age 12.9 
years) at the time of the echocardiogram and BMM marker measurements, and more often 
black (76%) and non-Hispanic (76%) than PHEU youth (mean age 11.1 years, 66% black, 
and 63% non-Hispanic). Systemic hypertension was rare and only observed among the 
PHIV youth (3%). For the subset of youth with available NT-proBNP and BMM markers, 
sociodemographic characteristics were similar to those shown in Table 1.
Among the PHIV youth in our study population, the majority were relatively healthy at the 
time of their echocardiogram, with most having high CD4 counts (>350 cells/mm3) and 68% 
having suppressed viral load. However, 25% had a prior AIDS-defining diagnosis (e.g., 
CDC Class C classification) and a high percentage of PHIV youth had a lifetime peak viral 
load exceeding 100,000 copies/mL (Table 1).
Summary of BMM marker measurements and echocardiographic variables
The 485 participants with evaluable echocardiograms and 25OHD specimens had a high 
prevalence of VDI, which was similar in the two groups (48% PHIV and 44% PHEU) (Table 
2). Children with VDI were significantly older than those with normal 25OHD 
concentrations (12.7 vs 11.8 years, respectively), more often black and Non-Hispanic, and 
had lower daily intake of Vitamin D (data not shown). Overall, the prevalence of elevated 
PTH was low (7%), but was significantly higher among PHIV (9%) than PHEU (3%) youth. 
PHIV youth had significantly lower median calcium and phosphate levels than PHEU, and 
tended to have higher FGF-23 concentrations than PHEU youth (Table 2).
PHIV youth showed significant differences in echocardiographic measures of LV structure 
and function compared to PHEU youth. In particular, PHIV youth demonstrated marginally 
lower LV ejection fraction and significantly lower fractional shortening than PHEU youth, 
and also had higher LV mass, LV ED and ES volumes, and LV ED dimension than PHEU 
youth. No difference was noted between groups in terms of log10 NT-proBNP (mean=1.51 
vs 1.54 pg/mL, respectively). These findings are consistent with previously published reports 
from this cohort (13).
Associations of BMM markers with echocardiographic measures and NT-proBNP 
concentrations
Cohort-wide, in unadjusted models, participants with VDI had statistically significantly 
higher mean systemic blood pressure Z-scores (−0.34 vs −0.57, p=0.006). However, they 
had lower mean Z-scores for LV mass, LV ED volume, and LV ES volume; youth with VDI 
also had significantly lower mean NT-proBNP concentrations than those with normal 
25OHD (Table 3). Echocardiographic z-scores rarely differed significantly by PTH status, 
although participants with elevated PTH had a significantly higher mean LV ED wall 
thickness in the unadjusted analysis (Table 4). Unadjusted models of echocardiographic 
outcomes indicated a significant positive association of ES wall stress with increasing 
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calcium levels, as well as a positive association between phosphate levels and LV ED wall 
thickness (data not shown).
After adjusting for HIV status and demographic characteristics, the above findings were 
attenuated. Adjusted mean z-scores generally no longer differed significantly by 25OHD 
(see Table 3) or PTH (Table 4) status. However, the association of VDI with significantly 
lower LV mass persisted. In addition, participants with elevated PTH concentrations had 
significantly higher fractional shortening and lower LV mass. In adjusted models, the 
positive association of calcium with ES wall stress persisted (beta=0.25, p=0.01) and a 
negative association was observed between calcium and log10 NT-proBNP (beta=−0.16, 
p=0.001). FGF-23 demonstrated a significant negative association with ED septal thickness 
(beta=−0.67, p=0.02).
Variations in associations by HIV infection status and within the PHIV group
Associations of 25OHD with echocardiographic parameters and log₁₀ NT-proBNP were 
evaluated to determine whether they varied by HIV infection status when adjusted for the 
covariates described. The association of VDI with lower mean z-scores for LV mass was 
similar within both PHIV and PHEU youth (data not shown). However, the association of 
VDI with ES wall stress was modified by HIV status, with similar means among PHIV 
youth with low and normal 25OHD (adjusted mean z-scores, −1.11 and −1.14, respectively), 
but higher ES wall stress among PHEU youth with low as compared to normal 25OHD 
(adjusted mean z-scores, −1.04 vs −1.51, interaction p=0.05). Within the PHIV group, 
neither VDI nor elevated PTH was significantly associated with any echocardiographic 
variable or with NT-proBNP concentrations in adjusted models. However, as in the overall 
sample, FGF-23 concentrations in the PHIV group were negatively associated with ED 
septal thickness (p=0.02) and higher calcium concentrations were associated with lower NT-
proBNP (p<0.001).
Associations between echocardiogram z-scores and BMM markers within racial 
subgroups
Analyses were conducted to determine whether the associations of BMM marker 
concentrations with cardiac outcomes were more pronounced among black participants. 
Many of the previously noted findings maintained the direction of association as the group-
wide analyses above, but were no longer statistically significant. The findings that 
demonstrated statistical significance are presented in Table 5. A significant association 
between 25OHD and contractility was observed in unadjusted analysis that was not present 
in the overall population, but none of the 25OHD associations remained significant after 
adjustment. Higher calcium was associated with higher LV ED dimension and lower NT-
proBNP, even after adjustment. The association between calcium and LV ED dimension was 
stronger among black youth than in the overall population. After adjustment, both calcium 
and phosphate concentrations were associated with lower NT-proBNP. Negative associations 
between FGF-23 and both ED septal thickness and M-mode thickness-to-dimension ratios 
were also noted after adjustment. There were insufficient numbers within other racial 
subgroups to justify such exploratory analyses.
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Abnormalities in BMM markers, especially low 25OHD concentrations, have long been 
associated with adverse cardiovascular conditions such as systemic hypertension, peripheral 
vascular disease, coronary artery disease, and congestive heart failure (CHF)5. The 
prevalence of other cardiovascular risk factors associated with these conditions, including 
hypercholesterolemia, insulin resistance, and lipodystrophy, are increased in children with 
HIV, particularly those taking protease inhibitors and nucleoside reverse transcriptase 
inhibitors16–18. Earlier detection of risk factors for development of these conditions would 
allow more timely and perhaps more effective interventions to prevent end-organ damage.
In this study of PHIV and PHEU children and adolescents, we sought to determine whether 
circulating concentrations of various BMM markers were associated with echocardiographic 
and cardiac biomarker abnormalities and, therefore, could potentially be early markers of 
altered cardiovascular health. We also evaluated whether any identified associations might 
be affected by HIV infection status (PHIV vs. PHEU). After adjustment for confounders, we 
found that participants with VDI or with elevated PTH had significantly lower LV mass z-
scores than those with normal concentrations of these two BMM markers. We also found 
that PTH levels were positively related to fractional shortening z-scores. In comparing the 
PHIV and PHEU groups, the only association modified by HIV status was the association 
between VDI and ES wall stress z-score: the difference in z-score values between those with 
normal 25OHD levels and those with VDI was larger in PHEU than in PHIV. When analysis 
was restricted to only the PHIV population, log10 FGF-23 was inversely related to ED septal 
thickness z-scores.
The associations of BMM markers with cardiac outcomes of LV wall thickness and mass in 
this study were not as originally hypothesized. VDI, elevated PTH levels, and elevated 
FGF-23 levels have all been associated with LV hypertrophy in various populations 
including: 25OHD in essential hypertension19 and chronic kidney disease20; PTH in 
coronary artery disease21 and primary hyperparathyroidism22; and FGF-23 in chronic kidney 
disease23. However, the significant findings reported here were in the opposite directions: 
VDI was associated with lower LV mass, as was elevated PTH. Thus, VDI and elevated PTH 
concentrations were associated with LV mass z-scores that were closer to the population 
norm. Additionally, ED septal thickness z-scores were inversely related to log10 FGF-23 
concentrations among all participants and also within the PHIV group. It is important to note 
that the mean z-scores for the cardiac outcome measures were within the normal range 
(between −2 and +2) for both functional and structural measures. The incidence of dilated 
cardiomyopathy in HIV disease has decreased dramatically in association with the advent of 
widespread ART utilization24. In the Pediatric Pulmonary and Cardiovascular Complications 
of HIV Study cohort, which enrolled subjects between May 1990 through April 1993, and 
collected serial echocardiographic data from birth through 10 years of age, 44% had 
cardiomyopathy, while only 4% of the AMP HIV-infected children, enrolled between 2007 
and 2009 and aged 7–16 years, did15. Because they are now uncommon, the ability to 
identify associations with more extreme cardiac abnormalities is unlikely. In the current 
relatively healthy population, other mechanisms or unknown additional confounders may be 
present, resulting in the unexpected observed associations.
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Few significant associations between BMM markers and cardiac functional measures (such 
as ejection fraction) were identified, despite the recognized association of derangements in 
mineral metabolism with clinical CHF. After adjusting for confounders, only the positive 
association of PTH on fractional shortening remained significant, an association that has 
been demonstrated in pediatric chronic renal failure where lower PTH levels have been 
shown to be associated with increases in CTnT (a biomarker of cardiac injury)8 and reduced 
cardiac function25.
Although the incidence of VDI and high PTH was higher in black youth4, their associations 
with cardiac outcomes were not statistically significant after adjusting for confounders. 
However, some associations between other components (calcium, phosphate, and FGF-23) 
and cardiac outcomes remained significant. For example, higher calcium levels and lower 
phosphate levels were associated with lower NT-proBNP levels, and higher FGF-23 levels 
were associated with lower thickness-to-dimension ratios and ED septal thickness (therefore, 
a tendency toward less hypertrophy). The incidence of type 2 diabetes, CHF, and stroke is 
higher in black persons26–28, and it is important to note that, although data are limited, 
cardiovascular risk factors, including insulin resistance, are highly prevalent in lower 
resource settings, as evaluated in the Children with HIV in Africa-Pharmacokinetics and 
Adherence/Acceptability of Simple Antiretroviral Regimens (CHAPAS)-3 trial.29 
Cardiometabolic abnormalities such as dyslipidemia and insulin resistance are also highly 
prevalent in other lower resourced pediatric HIV populations, as detailed by 
Padmapriyadarsini and colleagues30 Identifying screening tests to allow early interventions 
to prevent these conditions may be of particular benefit in these groups.
Strengths and Limitations of the Study
The PHACS AMP study cohort is comprised of large, well-characterized groups of PHIV 
and PHEU youth with echocardiograms performed by protocol and analyzed by a core 
laboratory and BMM marker samples obtained in conjunction with the echocardiogram. 
Only 33 (7%) of the 485 participants had elevated PTH concentrations; thus, the statistical 
power for comparisons in this group was limited. Originally, the study also sought to 
evaluate associations within the PHIV group by disease severity and type of antiretroviral 
medication, but the lack of observed associations made such evaluations unnecessary. Since 
only a single echocardiogram was conducted in each participant and BMM markers were 
measured only once within 6 months of the echocardiogram, we do not know the temporal 
relationship between our exposures and outcomes. Thus, we can only address association 
and not causation.
Conclusion
After adjusting for HIV status and demographic covariates, those with VDI had lower mean 
z-scores for LV mass, whereas those with elevated PTH had a higher mean z-score for 
fractional shortening and a lower mean z-score for LV mass. When analysis was restricted to 
only PHIV, few significant findings remained following adjustment for confounders, but 
log10 FGF-23 was inversely related to end-diastolic septal thickness. Associations were, 
therefore, noted in both structural and functional cardiac parameters, suggesting possible 
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links between bone mineral metabolism and cardiac status. By establishing expected 
relationships between commonly assessed parameters of cardiovascular health, such as 
structural and functional measures by echocardiography and cardiovascular biomarkers such 
as NT-proBNP, future interventional efforts with 25OHD supplementation may be 
facilitated. Furthermore, longitudinal studies may provide an opportunity to further clarify 
whether additional mechanisms or unmeasured confounders are responsible for the changes 
seen in structural and functional cardiac parameters. Finally, from a clinical standpoint, 
evidence of a link between bone mineral metabolism and cardiovascular outcomes provides 
clinicians with another potential mechanism of cardioprotection in this vulnerable 
population.
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Table 1.
Sociodemographic and health characteristics among 485 youth from the Adolescent Master Protocol of the 








Age, Mean (SD), years 12.89 (2.75) 11.09 (2.52)
Gender, n (%)
 Male 141 (46%) 88 (49%)
 Female 164 (54%) 92 (51%)
Race, n (%)
 White/Other 69 (24%) 59 (34%)
 Black 220 (76%) 117 (66%)
Hispanic Ethnicity 72 (24%) 65 (37%)
Body mass index z-score (Mean [SD]), z-score 0.40 (1.21) 0.70 (1.30)
Region, n (%)
 Northeast 112 (37%) 53 (29%)
 Midwest 50 (16%) 16 (9%)
 South 99 (33%) 58 (32%)
 West 31 (10%) 30 (17%)
 Puerto Rico 13 (4%) 23 (13%)
Dietary measures, Median (IQR)
 Total daily dietary intake of Vitamin D (IU) 172 (100, 345) 134 (82, 238)
 Total daily dietary intake of Calcium (mg) 727 (508, 1,005) 683 (502, 1000)
 Percent of calories from fat 34.0 (30.9, 37.9) 34.7 (31.0, 38.0)
 Percent of calories from protein 13.8 (12.3, 15.3) 14.0 (12.4, 15.8)
 Calories (0.001 kcal) 1.79 (1.20, 2.44) 1.53 (1.11, 2.14)
Moderate-to-vigorous physical activity
 < 30 min/day 74 (28%) 38 (23%)
 30–60 min/day 51 (20%) 33 (20%)
 60–120 min/day 61 (23%) 51 (30%)
 ≥ 120 min/day 77 (29%) 46 (27%)
Systemic hypertension, n (%) 8 (3%) 0 (0%)
CD4 T-cell count (cells/μL) < 350 cells/μL, n (%) 32 (11%)
Nadir CD4 T-cell percent < 15%, n (%) 104 (35%)
HIV-1 RNA (copies/mL) ≤ 400 copies/mL, n (%) 203 (68%)
Peak HIV-1 RNA (copies/mL) ≥ 100,000 copies/mL, n (%) 224 (75%)
ART regimen at assessment, n (%)
 ART with protease inhibitor 211 (69%)
 ART without protease inhibitor 57 (19%)
 Non-ART ARV 19 (6%)
 Not on ARV 17 (6%)
Duration on cART, Median (IQR), years 8.92 (6.27, 10.59)





















CDC HIV Class C, n (%) 76 (25%)
SD=standard deviation, IQR=interquartile range (25th, 75th percentiles), PI=protease inhibitor
1
Some characteristics were not measured or obtained for certain variables, including race (n=20; 16 PHIV 4 PHEU), ethnicity (n=3, all PHEU), 
dietary measures (n=28; 17 PHIV, 11 PHEU), physical activity from BLOCK physical activity questionnaire; not completed (n=45; 42 PHIV, 12 
PHEU). CD4 and HIV-1 RNA measures were included if obtained 183 days prior to and up to 7 days after the date of the echocardiogram.
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Table 2.
Distribution of concentrations of bone mineralization metabolism markers by HIV status among 485 youth 
from the Adolescent Master Protocol of the Pediatric HIV/AIDS Cohort Study with evaluable 
echocardiograms and serum specimens
Cohort
P-Value




Serum concentrations, median (IQR)
1
 25OHD (ng/mL) 20.3 (15.3, 25.9) 20.9 (17.0, 26.7) 0.32
 Calcium (mg/dL) 9.52 (9.22, 9.80) 9.65 (9.39, 9.92) < 0.001
 Phosphate (mg/dL) 4.48 (4.01, 4.88) 4.82 (4.36, 5.21) < 0.001
 PTH (pg/mL) 32.4 (23.5, 45.0) 28.6 (22.0, 40.0) 0.005
 FGF-23 (RU/mL) 1.55 (1.42, 1.67) 1.48 (1.43, 1.58) 0.11
Categories of 25OHD and PTH
 Low 25OHD (< 20 ng/mL), n (%) 147 (48%) 79 (44%) 0.36
 Elevated PTH (> 65 pg/mL), n (%) 27 (9%) 6 (3%) 0.02
 25OHD < 20 ng/mL or PTH > 65 pg/mL, n (%) 157 (51%) 79 (44%) 0.11
IQR=interquartile range (25th percentile, 75th percentile); PTH=parathyroid hormone; FGF=fibroblast growth factor; RU=Relative Unit.
1
Serum concentrations were not measured for 1 participant for calcium (PHIV), for 3 participants for PTH (1 PHIV, 2 PHEU), and for 246 
participants for FGF-23 (160 PHIV, 86 PHEU).
2
p-value by Wilcoxon rank sum test for comparison of medians and by Chi-Square test for comparison of proportions.
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Table 3.
Association of cardiac outcomes by 25OHD status among participants from the Adolescent Master Protocol of 
the Pediatric HIV/AIDS Cohort Study
Cardiac Outcomes
Unadjusted Means (SE), z-score Adjusted Means (SE)
1
, z-score
N Low 25OHD Normal 25OHD P-value N Low 25OHD Normal 25OHD P-value
Primary Outcome Measures
 Fractional Shortening 483 0.17 (0.06) 0.19 (0.06) 0.79 429 0.20 (0.08) 0.21 (0.06) 0.92
 LV Mass 470 0.08 (0.06) 0.37 (0.06) 0.001 400 0.18 (0.07) 0.37 (0.06) 0.05
 Contractility 393 0.20 (0.07) 0.26 (0.07) 0.55 339 0.20 (0.08) 0.24 (0.07) 0.72
 LV ED Wall Thickness 477 −0.18 (0.06) −0.12 (0.06) 0.44 406 −0.16 (0.07) −0.10 (0.06) 0.52
 ED Septal Thickness 477 −0.51 (0.06) −0.45 (0.05) 0.43 406 −0.51 (0.07) −0.47 (0.06) 0.61
 NT-proBNP (pg/mL) 383 1.42 (0.03) 1.51 (0.03) 0.05 334 1.44 (0.04) 1.48 (0.04) 0.42
Secondary Outcome Measures
 LV ED Volume 471 −0.08 (0.07) 0.16 (0.06) 0.01 401 −0.03 (0.07) 0.06 (0.06) 0.34
 LV ES Volume 471 −0.17 (0.07) 0.11 (0.06) 0.003 401 −0.09 (0.07) 0.01 (0.06) 0.29
 LV Ejection Fraction 472 0.02 (0.06) 0.04 (0.06) 0.83 402 0.03 (0.07) 0.01 (0.06) 0.86
 LV ED Dimension 477 −0.36 (0.07) −0.22 (0.07) 0.13 406 −0.26 (0.08) −0.25 (0.07) 0.86
 M-Mode Thickness-to-Dimension Ratio 478 −0.25 (0.06) −0.32 (0.05) 0.43 407 −0.30 (0.07) −0.27 (0.06) 0.73
 ES Wall Stress 406 −1.04 (0.08) −1.22 (0.07) 0.09 366 −1.11 (0.09) −1.31 (0.08) 0.07
LV=left ventricular; ED=end-diastolic; ES=end-systolic; NT-proBNP= b-type natriuretic peptide; SE=standard error
1
Association between cardiac outcomes and 25OHD status based on linear regression models adjusted for HIV status, age, sex, race, BMI z-score, 
and physical activity for all cardiac outcomes, except fractional shortening (adjusted for HIV status, region, and physical activity) and ES wall 
stress (adjusted for HIV status, age, region, and physical activity).
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Table 4.
Association of cardiac outcomes by PTH status among participants from the Adolescent Master Protocol of 
the Pediatric HIV/AIDS Cohort Study
Cardiac Outcomes
Unadjusted Means (SE), z-score Adjusted Means (SE)
1
, z-score
N Elevated PTH Normal PTH P-value N Elevated PTH Normal PTH P-value
Primary Outcome Measures
 Fractional Shortening 480 0.38 (0.16) 0.16 (0.04) 0.20 426 0.55 (0.18) 0.18 (0.05) 0.05
 LV Mass 467 −0.04 (0.16) 0.25 (0.05) 0.08 397 −0.05 (0.17) 0.31 (0.05) 0.05
 Contractility 390 0.26 (0.19) 0.23 (0.05) 0.89 336 0.26 (0.22) 0.22 (0.06) 0.87
 LV ED Wall Thickness 474 0.17 (0.15) −0.17 (0.04) 0.04 403 0.15 (0.18) −0.13 (0.05) 0.13
 ED Septal Thickness 474 −0.32 (0.14) −0.48 (0.04) 0.27 403 −0.45 (0.16) −0.48 (0.05) 0.83
 Log10 NT-proBNP (pg/mL) 380 1.43 (0.09) 1.48 (0.02) 0.63 331 1.47 (0.10) 1.48 (0.03) 0.91
Secondary Outcome Measures
 LV ED Volume 468 0.06 (0.17) 0.04 (0.05) 0.91 398 −0.08 (0.17) 0.02 (0.05) 0.57
 LV ES Volume 468 −0.07 (0.18) −0.01 (0.05) 0.73 398 −0.20 (0.17) −0.01 (0.05) 0.29
 LV Ejection Fraction 469 −0.04 (0.15) 0.03 (0.04) 0.67 399 0.09 (0.18) 0.00 (0.05) 0.64
 LV ED Dimension 474 −0.19 (0.18) −0.30 (0.05) 0.56 403 −0.36 (0.19) −0.25 (0.05) 0.57
 M-Mode Thickness-to-Dimension Ratio 475 −0.03 (0.15) −0.30 (0.04) 0.077 404 −0.00 (0.17) −0.29 (0.05) 0.09
 ES Wall Stress 403 −1.36 (0.20) −1.11 (0.05) 0.21 363 −1.50 (0.21) −1.22 (0.06) 0.19
LV=left ventricular; ED=end-diastolic; ES=end-systolic; NT-proBNP=b-type natriuretic peptide; SE=standard error
1
Association between cardiac outcomes and 25OHD status based on linear regression models adjusted for HIV status, age, sex, race, BMI z-score, 
and physical activity for all cardiac outcomes, except fractional shortening (adjusted for HIV status, region, and physical activity) and ES wall 
stress (adjusted for HIV status, age, region, and physical activity).
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Table 5.
Associations of bone mineral metabolism markers with cardiac outcomes among black participants in the 
Adolescent Master Protocol of the Pediatric HIV/AIDS Cohort Study
25OHD status
Cardiac Outcomes Unadjusted Means (SE) Adjusted Means (SE)
1
N Low Normal P-value N Low Normal P-value
Contractility, z-score 269 0.16 (0.08) 0.38 (0.08) 0.05 239 0.19 (0.09) 0.37 (0.09) 0.16
LV Mass, z-score 325 0.03 (0.07) 0.27 (0.08) 0.02 283 0.07 (0.07) 0.21 (0.08) 0.20
LV ED Volume, z-score 326 −0.13 (0.07) 0.10 (0.08) 0.04 284 −0.11 (0.07) −0.02 (0.08) 0.37
LV ES Volume, z-score 326 −0.19 (0.08) 0.05 (0.08) 0.03 284 −0.15 (0.07) −0.09 (0.08) 0.54
Calcium
N Unadjusted Estimate (SE) P-value N Adjusted Estimate (SE)* P-Value
LV ED Dimension, z-score 331 0.18 (0.10) 0.05 289 0.20 (0.10) 0.04
ES Wall Stress, z-score 279 0.25 (0.11) 0.02 249 0.20 (0.12) 0.08
NT-proBNP (pg/mL) 256 −0.07 (0.05) 0.16 231 −0.16 (0.05) 0.004
Phosphate
N Unadjusted Estimate (SE) P-value N Adjusted Estimate (SE)* P-Value
LV Mass, z-score 325 0.20 (0.07) 0.005 283 0.14 (0.08) 0.06
LV ES Volume, z-score 326 0.15 (0.08) 0.05 284 0.03 (0.07) 0.67
NT-proBNP (pg/mL) 257 0.00 (0.04) 0.96 232 −0.08 (0.04) 0.05
Log10 FGF-23
N Unadjusted Estimate (SE) P-value N Adjusted Estimate (SE)* P-Value
M-Mode Thickness-to-Dimension Ratio, z-
score
164 −0.28 (0.30) 0.35 144 −0.66 (0.34) 0.05
ED Septal Thickness, z-score 164 −0.79 (0.30) 0.01 144 −0.77 (0.34) 0.03
LV=left ventricular; ED=end-diastolic; ES=end-systolic; NT-proBNP=b-type natriuretic peptide; SE=standard error
1
Association between cardiac outcomes and individual bone mineral metabolism markers is adjusted by HIV status, age, sex, BMI z-score, and 
physical activity for all cardiac outcomes, except Fractional Shortening and ES Wall Stress. The model fitting the association between Fractional 
Shortening z-score and individual bone mineral metabolism markers is adjusted by HIV status, region, and physical activity, while that between ES 
Wall Stress and individual bone mineral metabolism markers is adjusted by HIV status, age, region, and physical activity.
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